Marten Steen Net Worth

Marten Steen biography

Dr. Marten Steen M.D. Ph.D. serves as Independent Director of the Company. He has served as a Partner of HealthCap VI, L.P., a venture capital firm investing in life science companies. Prior to HealthCap, from February 2008 until March 2010, Dr. Steen served as director at Merck Serono SA, a biopharmaceutical company. Currently, he serves as a member of the board of directors of BioClin Therapeutics, Inc. He previously served on the boards of Ultragenyx Pharmaceutical Inc., Wilson Therapeutics AB, Altimmune, Inc. and FerroKin Biosciences. Dr. Steen holds a B.Sc. in Business Administration, an M.D., and a Ph.D. in Clinical Chemistry, all from Lund University.

What is the salary of Marten Steen?

As the Independent Director of Strongbridge Biopharma plc, the total compensation of Marten Steen at Strongbridge Biopharma plc is $277,526. There are 3 executives at Strongbridge Biopharma plc getting paid more, with Frederic Cohen having the highest compensation of $1,093,830.

How old is Marten Steen?

Marten Steen is 44, he's been the Independent Director of Strongbridge Biopharma plc since 2014. There are 8 older and no younger executives at Strongbridge Biopharma plc. The oldest executive at Strongbridge Biopharma plc is David Gill, 65, who is the Independent Director.

What's Marten Steen's mailing address?

Marten's mailing address filed with the SEC is 900 NORTHBROOK DRIVE, SUITE 200, TREVOSE, PA, 19053.

Insiders trading at Strongbridge Biopharma plc

Over the last 7 years, insiders at Strongbridge Biopharma plc have traded over $0 worth of Strongbridge Biopharma plc stock and bought 2,670,648 units worth $8,846,818 . The most active insiders traders include Associates, L.L.C.Caxton Co..., Garheng Kong, and Jeffrey W Sherman. On average, Strongbridge Biopharma plc executives and independent directors trade stock every 89 days with the average trade being worth of $593,478. The most recent stock trade was executed by David N Gill on 24 September 2020, trading 8,000 units of SBBP stock currently worth $17,040.

What does Strongbridge Biopharma plc do?

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's rare endocrine franchise includes RECORLEV® (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing's syndrome, and veldoreotide extended release, a preclinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company's rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.

Strongbridge Biopharma plc executives and stock owners

Strongbridge Biopharma plc executives and other stock owners filed with the SEC include:

• Frederic Cohen,
  Chief Medical Officer
• Robert Lutz,
  Chief Financial Officer
• John Johnson,
  Chief Executive Officer
• Marten Steen,
  Independent Director
• Garheng Kong,
  Lead Independent Director
• Richard Kollender,
  Chief Operating Officer
• Hilde Steineger,
  Independent Director
• Jeffrey Sherman,
  Independent Director
• David Gill,
  Independent Director
• Stephen Long,
  Secretary, Chief Legal Officer
• Scott Wilhoit,
  Chief Commercial Officer
• A Brian Davis,
  Chief Financial Officer
• Matthew Pauls,
  President & CEO
• Fredric J. Cohen,
  Chief Medical Officer
• Associates, L.L.C.Caxton Co...,